BSE Live
Apr 08, 16:01Prev. Close
34.62
Open Price
36.35
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Shukra Pharmaceuticals (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 0.84 | -0.64 | -2.48 | 0.81 | 0.58 | |
| Diluted EPS (Rs.) | 0.84 | -4.87 | -2.48 | 0.81 | 0.58 | |
| Cash EPS (Rs.) | 4.67 | 0.11 | -2.16 | 1.56 | 1.11 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 89.13 | 88.29 | -0.42 | 1.64 | 0.58 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 89.13 | 88.29 | -0.42 | 1.64 | 0.58 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 16.45 | 28.15 | 5.03 | 7.38 | 10.98 | |
| PBDIT/Share (Rs.) | 5.55 | 0.62 | 0.53 | 0.33 | 1.38 | |
| PBIT/Share (Rs.) | 1.71 | -4.36 | -0.19 | -0.17 | 1.02 | |
| PBT/Share (Rs.) | 1.71 | -4.45 | -0.22 | -0.19 | 0.76 | |
| Net Profit/Share (Rs.) | 0.84 | -4.87 | -2.88 | 1.06 | 0.76 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 33.72 | 2.19 | 10.53 | 4.44 | 12.58 | |
| PBIT Margin (%) | 10.42 | -15.48 | -3.72 | -2.28 | 9.33 | |
| PBT Margin (%) | 10.37 | -15.80 | -4.29 | -2.55 | 6.90 | |
| Net Profit Margin (%) | 5.08 | -17.30 | -57.31 | 14.38 | 6.90 | |
| Return on Networth / Equity (%) | 0.93 | -5.51 | 0.00 | 64.74 | 131.05 | |
| Return on Capital Employed (%) | 0.75 | -4.68 | -1.61 | 6.78 | 27.20 | |
| Return on Assets (%) | 0.71 | -4.29 | -21.64 | 5.97 | 6.02 | |
| Total Debt/Equity (X) | 0.09 | 0.02 | -23.49 | 7.12 | 10.07 | |
| Asset Turnover Ratio (%) | 14.06 | 24.84 | 37.76 | 41.56 | 87.27 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 7.87 | 4.46 | 1.93 | 7.13 | 1.02 | |
| Quick Ratio (X) | 6.32 | 3.67 | 1.23 | 6.65 | 0.95 | |
| Inventory Turnover Ratio (X) | 1.91 | 3.88 | 4.15 | 7.23 | 15.36 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 0.85 | 0.04 | 11.40 | 12.75 | 5.44 | |
| EV/Net Operating Revenue (X) | 0.33 | 0.01 | 2.23 | 1.92 | 0.55 | |
| EV/EBITDA (X) | 0.98 | 0.44 | 21.17 | 43.28 | 4.39 | |
| MarketCap/Net Operating Revenue (X) | 0.10 | 0.06 | 0.27 | 0.35 | 0.05 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | |
| Price/BV (X) | 0.02 | 0.02 | -3.17 | 1.56 | 0.87 | |
| Price/Net Operating Revenue | 0.10 | 0.06 | 0.27 | 0.35 | 0.05 | |
| Earnings Yield | 0.53 | -3.10 | -2.15 | 0.41 | 1.51 |
10.02.2026
Shukra Pharma Consolidated December 2025 Net Sales at Rs 39.13 crore, up 269.74% Y-o-Y
09.02.2026
Shukra Pharma Standalone December 2025 Net Sales at Rs 39.13 crore, up 269.74% Y-o-Y
24.11.2025
Shukra Pharma Standalone September 2025 Net Sales at Rs 5.88 crore, up 5.8% Y-o-Y
12.06.2025
Shukra Pharma Standalone March 2025 Net Sales at Rs 13.27 crore, up 21.92% Y-o-Y
08.04.2026
Indian CDMOs face tariff exposure via patented drug supply chains
08.04.2026
08.04.2026
07.04.2026
Kiran Mazumdar‑Shaw calls for new IPO rules to unlock India’s innovation potential in life sciences
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth